Your browser doesn't support javascript.
loading
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.
Fachal, Laura; Gómez-Caamaño, Antonio; Barnett, Gillian C; Peleteiro, Paula; Carballo, Ana M; Calvo-Crespo, Patricia; Kerns, Sarah L; Sánchez-García, Manuel; Lobato-Busto, Ramón; Dorling, Leila; Elliott, Rebecca M; Dearnaley, David P; Sydes, Matthew R; Hall, Emma; Burnet, Neil G; Carracedo, Ángel; Rosenstein, Barry S; West, Catharine M L; Dunning, Alison M; Vega, Ana.
Afiliação
  • Fachal L; 1] Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain. [2] Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
  • Gómez-Caamaño A; Department of Radiation Oncology, USC University Hospital Complex, SERGAS, Santiago de Compostela, Spain.
  • Barnett GC; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Peleteiro P; Department of Radiation Oncology, USC University Hospital Complex, SERGAS, Santiago de Compostela, Spain.
  • Carballo AM; Department of Radiation Oncology, USC University Hospital Complex, SERGAS, Santiago de Compostela, Spain.
  • Calvo-Crespo P; Department of Radiation Oncology, USC University Hospital Complex, SERGAS, Santiago de Compostela, Spain.
  • Kerns SL; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Sánchez-García M; Department of Medical Physics, USC University Hospital Complex, SERGAS, Santiago de Compostela, Spain.
  • Lobato-Busto R; Department of Medical Physics, USC University Hospital Complex, SERGAS, Santiago de Compostela, Spain.
  • Dorling L; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Elliott RM; Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, UK.
  • Dearnaley DP; Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, UK.
  • Sydes MR; Cancer and Other Non-Infectious Diseases, Medical Research Council (MRC) Clinical Trials Unit, London, UK.
  • Hall E; Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
  • Burnet NG; Department of Oncology, University of Cambridge, Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Carracedo Á; 1] Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain. [2] Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain. [3
  • Rosenstein BS; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • West CM; Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, UK.
  • Dunning AM; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Vega A; 1] Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain. [2] Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
Nat Genet ; 46(8): 891-4, 2014 Aug.
Article em En | MEDLINE | ID: mdl-24974847
There is increasing evidence supporting the role of genetic variants in the development of radiation-induced toxicity. However, previous candidate gene association studies failed to elucidate the common genetic variation underlying this phenotype, which could emerge years after the completion of treatment. We performed a genome-wide association study on a Spanish cohort of 741 individuals with prostate cancer treated with external beam radiotherapy (EBRT). The replication cohorts consisted of 633 cases from the UK and 368 cases from North America. One locus comprising TANC1 (lowest unadjusted P value for overall late toxicity=6.85×10(-9), odds ratio (OR)=6.61, 95% confidence interval (CI)=2.23-19.63) was replicated in the second stage (lowest unadjusted P value for overall late toxicity=2.08×10(-4), OR=6.17, 95% CI=2.25-16.95; Pcombined=4.16×10(-10)). The inclusion of the third cohort gave unadjusted Pcombined=4.64×10(-11). These results, together with the role of TANC1 in regenerating damaged muscle, suggest that the TANC1 locus influences the development of late radiation-induced damage.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Lesões por Radiação / Cromossomos Humanos Par 2 / Loci Gênicos Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans / Male País/Região como assunto: Europa Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Lesões por Radiação / Cromossomos Humanos Par 2 / Loci Gênicos Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans / Male País/Região como assunto: Europa Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos